MDX RA
Alternative Names: 4197X-RA; Monoclonal antibody ricin ALatest Information Update: 20 Feb 2006
At a glance
- Originator Houston Biotechnology
- Class Drug conjugates; Eye disorder therapies; Immunotoxins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cataracts
Most Recent Events
- 18 May 2004 Suspended - Preclinical for Cataracts in Japan (unspecified route)
- 31 Jan 2002 The collaboration between Scil Biomedicals and Medarex has ended
- 31 Oct 2000 IDM has acquired certain economic interests in MDX RA as part of an expansion of its partnership with Medarex